Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion
TL;DR
Gilead Sciences has announced the acquisition of CymaBay Therapeutics for $4.3 billion, adding seladelpar, an investigational treatment for primary biliary cholangitis (PBC), to its liver portfolio. Seladelpar, with FDA priority review and anticipated U.S. approval in the third quarter of 2024, has shown promising results in Phase 3 trials, offering a potential treatment for PBC, a rare liver disease. The acquisition aligns with Gilead's commitment to addressing unmet needs in liver diseases and is expected to enhance its revenue growth upon FDA approval of seladelpar.
Topics:businesshealth-and-pharmaceuticals#acquisition#cymabay-therapeutics#gilead-sciences#health-and-pharmaceuticals#liver-diseases#seladelpar
- Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics Gilead Sciences
- CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal The Wall Street Journal
- CymaBay's stock surges as Gilead reaches $4.3 billion deal for liver-drug developer MarketWatch
- Gilead to Buy Liver Disease Biotech CymaBay Therapeutics for $4.3 Billion Barron's
- Gilead pays $4.3B for CymaBay's late-stage liver disease med FierceBiotech
Want the full story? Read the original reporting
Read on Gilead Sciences